PALSONIFY's sequential revenue doubling and expanding prescriber base validate commercial execution, but the stock may not react strongly as the company remains pre-profitability with a widening net loss. Watch for the Phase 2/3 Cushing's trial initiation in Q2 2026 and European revenue contribution in H2 2026 as key catalysts.
Price Chart
Executive Summary
Crinetics reported Q1 2026 revenue of $10.7M (vs $0.4M YoY), driven by $10.3M in PALSONIFY net product revenue, nearly doubling Q4 2025's $5.4M. Net loss widened to $127.8M from $96.8M YoY due to increased R&D and SG&A spend. The company maintained its 2026 GAAP operating expense guidance of $600M-$650M, and the European Commission approved PALSONIFY in April 2026, expanding the commercial opportunity.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $10.7M vs $0.4M YoY; net product revenue $10.3M
- PALSONIFY net product revenue nearly doubled sequentially from $5.4M in Q4 2025
- 232 enrollment forms received in Q1 2026; 263 unique HCPs prescribed PALSONIFY in first two quarters of launch
- Net loss $127.8M vs $96.8M YoY; R&D expenses $100.1M vs $76.2M YoY
- Cash, equivalents, and securities $1.3B as of March 31, 2026, including $380M from January 2026 equity offering
- European Commission approved PALSONIFY in April 2026; MAA submitted in Brazil; NDA submitted in Japan
- 2026 GAAP operating expense guidance maintained at $600M-$650M
- Phase 2/3 trial for atumelnant in ACTH-dependent Cushing's syndrome on track to initiate in Q2 2026
Financial Impact
Revenue growth from $0.4M to $10.7M YoY; net loss increased $31M YoY to $127.8M
Risk Factors
- Net loss widening faster than revenue growth; operating expenses up 35% YoY
- Dependence on single product PALSONIFY for near-term revenue
- Clinical trial risks for atumelnant and pipeline candidates
- Cash burn rate; $1.3B provides runway but equity dilution risk remains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001658247-26-000039 |
| Document: crnx-20260507.htm | 0001658247-26-000039 |
| Document: 0001658247-26-000039-index-headers.html | 0001658247-26-000039 |
| Document: 0001658247-26-000039-index.html | 0001658247-26-000039 |
| Document: 0001658247-26-000039.txt | 0001658247-26-000039 |
| 8-K Data (Synthetic) | 0001658247-26-000039 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 15-12G | — | awaiting T+1 | — | — |
Sep 1, 2026 4w ago | 25-NSE | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Sep 1, 2026 4w ago | 8-K | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Aug 14, 2026 7w ago | 8-K | $84.70 $84.75 | ▲ +0.06% | ▲ +0.53% | — |
Aug 3, 2026 8w ago | Press Release | $83.86 $84.00 | ▲ +0.17% | ▲ +0.37% | — |
Jul 10, 2026 12w ago | DEFA14A | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jul 10, 2026 12w ago | 8-K | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jun 30, 2026 13w ago | Press Release | $38.68 $42.23 | ▲ +9.18% | ▲ +9.31% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access